REGULATORY
Japan Political Parties Push Varied Pharma Policies as Election Campaign Kicks Off
By Ken Yoshino October 15, 2024
Japan’s Lower House election campaign officially kicked off on October 15, with voting set to take place on October 27. All main political parties embrace some kind of pharmaceutical measure in their policy pledges, but…

LATEST

October 16, 2024
Janssen Pharmaceutical (J&J) said on October 11 that its bispecific antibody teclistamab delivered clinically meaningful, deep and durable responses in Japanese patients with relapsed or refractory multiple myeloma (MM) in a PI/II follow-up study.The drug…
October 16, 2024
CarbGeM, a Japanese startup specializing in AI-powered diagnostics, said on October 15 that it has formed a collaborative research partnership with the University of Zurich focusing on bacterial persistence among ESKAPE pathogens and other bacteria.Under the collaboration, clinical isolates from…
October 16, 2024
Daiichi Sankyo has snared conditional approval in China for its antibody drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) for an additional indication of certain patients with HER2 mutated non-small cell lung cancer (NSCLC).The drug was approved…
By Shinya Sato

Japan introduced a new health coverage scheme for long-listed products (LLPs) on October 1. A survey of generic drug makers…

By Philip Carrigan

It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…

A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…

A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…

The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

By Yoshinori Sagehashi

The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…

A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…

Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…

Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…

NEWS CATEGORY

REGULATORY

BUSINESS

ORGANIZATION

ACADEMIA